Revisit Neuronetics with updates on operations, financial performance, and outlook. Click to read how recent developments ...
Study lead Dr. Angharad de Cates told Newsweek: "Our findings offer promise for addressing cognitive problems in depression." ...
CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026. She ...
Xenon nears a Q3 2026 NDA with strong Phase 3 epilepsy data and a cash runway to 2029. Click here to read an analysis of XENE ...
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc ...
An existing constipation drug may have an unexpected new use: helping clear the "brain fog" that often lingers after ...
A new study found that adults with disabilities had more than three times the rate of AUD diagnoses compared with adults ...
As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have ...
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the ...
The Break Up Big Medicine Act has bipartisan support, and builds on new laws restricting pharmacy benefit managers.
Axsome Therapeutics is running phase 3 studies for AXS-14, an investigational medicine for fibromyalgia, and it plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results